The immunoassay segment accounts about 35% of the market, with no growth compared to the previous year. Domestic brands account for over 35%. 

Molecular diagnostics make up over 10% of the market, with no growth compared to last year. Domestic brands hold about 50%. In 2024, molecular diagnostic technologies are continuously expanding in routine disease diagnosis applications, with great potential in accurate diagnostics and health management for respiratory diseases, maternal and child health, early cancer screening, and chronic disease management. However, domestic technological development and application are still in early stages. The industry remains fragmented, and molecular diagnostics in clinical settings are trending toward point-of-care testing. 

The blood and body fluid testing market holds about 10% share, with growth exceeding 5%. Domestic brands account for over 50%. Routine testing items have shown recovery from a low base.  

The POC testing market holds about 15% share, growing around 5%, with domestic brands holding over 60%. In 2024, China’s POC market has rebounded, particularly in chronic disease management linked to outpatient visits, which has seen steady growth. However, demand for respiratory infectious disease testing fluctuates seasonally. In the following years, the localization of innovative POC technologies and the improvement of primary healthcare resources will remain the main drivers of growth in China’s POC industry.  

The microbiology market accounts for 5% of the IVD market, with growth around 5%. Domestic brands hold about 20%. In 2024, demand in the microbiological testing market remains stable, with growth driven by policy support for infectious disease departments in top-tier hospitals, rising incidence of infectious diseases, and increased research into the connection between chronic diseases and microbiology.

Last: The Annual Report of China IVD Industry 2024 – Chapter 2: China IVD Market